Blog Archives

Understanding the Value of Medication: Whose job is it?

There has been a lot of discussion about drugs and drug pricing of late, including the idea of value-based purchasing.  One element, though, that hasn’t been getting quite enough attention is just how a patient or a pharmacist or a

Tagged with: , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

What’s Old is New Again: Proposals to Rein in Drug Prices are Nothing New

It used to be that Americans would look the other way when it came to drug prices, concluding that the benefit outweighed the costs.  However, with prices continuing their march upward and with more of that price being borne directly

Tagged with: , , , , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

A Major Loss for Consumers: FDA Proposed Rule on Biosimilar Naming Threatens Savings and Offers No Gain in Safety

This morning’s proposed rule on biosimilar naming marks a major win for PhRMA and BIO and a loss for consumers, not to mention a reversal of FDA policy.  At a time when more than 70% of Americans believe drug companies

Tagged with: , , , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

More Questions Than Answers: The Biosimilar Pathway

It’s not that often in the legal world that truly novel questions are presented, the kind to which lawyers can only offer answers in conjectures and hopes rather than opinions.  Now is such a time as the first biosimilar case

Tagged with: , , ,
Posted in Biosimilars, Pharmaceuticals

Why Should I, A Self-Professed Health Policy Nerd, Care About the Trans-Pacific Partnership (TPP) Trade Agreement?

Trade negotiations are the stuff of legend around here – high stakes politics and international business, all transacted behind closed doors with the strictest of confidentiality measures in place.  That said, I don’t always pay them much attention.  This time

Tagged with: , , ,
Posted in Biosimilars, Pharmaceuticals